Among these, LNCaP represents a hormone-sensitive cell line, whereas the other cancer cell lines exhibit resistance to androgen synthesis inhibitor abiraterone and androgen receptor (AR)-inhibitors such as enzalutamide. The gene discussed is AR; the disease is cancer.